SHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies.

ABSTRACT:

Background

The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) in first- and second-line antiretroviral therapy (ART) may facilitate emerging resistance. We combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for DTG resistance.

Methods

Eight cohorts from Canada, Europe, and South Africa contributed data on individuals with genotypic resistance testing on DTG-based ART. Resistance levels were categorised using the Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic regression models.

Results

We included 750 people with genotypic resistance testing on DTG-based ART between 2013 and 2022. Most had HIV subtype B (N=444, 59·2%) a

SUBMITTER: Loosli T 

PROVIDER: S-EPMC10104228 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature